Trial · NCT00771030
Results by group105
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 105
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | Placebo SC (Cohorts 1-3) | Any treatment-emergent adverse event (TEAE) | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Placebo IV (Cohorts 5-6) | Any treatment-emergent adverse event (TEAE) | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 50 mg SC (Cohort 1) | Any treatment-emergent adverse event (TEAE) | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 140 mg SC (Cohort 2) | Any treatment-emergent adverse event (TEAE) | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 210 mg SC (Cohort 3) | Any treatment-emergent adverse event (TEAE) | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 420 mg IV (Cohort 5) | Any treatment-emergent adverse event (TEAE) | 5 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 700 mg IV (Cohort 6) | Any treatment-emergent adverse event (TEAE) | 4 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Placebo SC (Cohorts 1-3) | Serious TEAEs | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Placebo IV (Cohorts 5-6) | Serious TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 50 mg SC (Cohort 1) | Serious TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 140 mg SC (Cohort 2) | Serious TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 210 mg SC (Cohort 3) | Serious TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 420 mg IV (Cohort 5) | Serious TEAEs | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 700 mg IV (Cohort 6) | Serious TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Placebo SC (Cohorts 1-3) | Treatment-related TEAEs | 1 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Placebo IV (Cohorts 5-6) | Treatment-related TEAEs | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 50 mg SC (Cohort 1) | Treatment-related TEAEs | 0 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 140 mg SC (Cohort 2) | Treatment-related TEAEs | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 210 mg SC (Cohort 3) | Treatment-related TEAEs | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events | Brodalumab 420 mg IV (Cohort 5) | Treatment-related TEAEs | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00771030/results